MTOR and neoplasm with perivascular epithelioid cell differentiation: The fact mTOR inhibitor ridaforolimus failed to be approved after the randomized clinical trials for all sarcomas, though that the drug responses to a particularly effective subtype (PEComa) was an also lesson.